NORCROSS, Ga., June 19 /PRNewswire-FirstCall/ -- Immucor, Inc. , a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced today that the U.S. Food and Drug Administration has cleared Galileo Echo(TM) for marketing in the United States as of June 14, 2007. Echo, Immucor’s third generation automated assay instrument, is a compact bench top, fully automated walk-away instrument for the small to medium sized hospital blood bank transfusion laboratory.
Commenting on this clearance Dr. Gioacchino De Chirico, President and CEO stated, “This is a major milestone in the history of Immucor. The Echo offers small to medium sized hospitals and laboratories a full test menu and significant labor reduction while increasing productivity and patient safety. We believe the worldwide total available market for Echo is approximately 6,000.”
Commenting further, Dr. Gioacchino De Chirico, stated, “Echo has true continuous access performing all the routine blood bank tests including ABO grouping and Rh (D) typing, detection/ identification of IgG red blood cell antibodies, compatibility testing and red blood cell phenotyping. We are also very pleased to announce Echo and its associated reagents were recently registered as CE marked IVD devices (products) for distribution in Europe.”
Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of our market segments.
For more information on Immucor, please visit our website at www.immucor.com.
Statements contained in this press release that are not statements of historical fact are “forward-looking statements” as that term is defined under federal securities laws. Investors are cautioned not to place undue reliance on any forward-looking statements. In particular, nothing in this press release, including but not limited to the Company’s belief about the size of the market for Echo, should be viewed as a projection of how many Echo instruments the Company expects to sell. Further risks are detailed in the Company’s filings with the Securities and Exchange Commission. Immucor assumes no obligation to update any forward-looking statements.
Immucor, Inc.
CONTACT: Patrick Waddy, +1-770-441-2051, for Immucor, Inc.
Web site: http://www.immucor.com/
